Efficacy of Ericksonian Hypnosis in the Management of Chronic Pain Related to Parkinson's Disease
CompletedNot applicableNCT04259203
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study evaluates the efficacity of Erickson hypnosis in the treatment of chronic pain in patients with Parkinson's disease. Half of participants will follow a 2-month Erickson hypnosis protocole, while the other half will benefit from the usual care.
Study details
- Official title
- Efficacy of Ericksonian Hypnosis in the Management of Chronic Pain Related to Parkinson's Disease
- Conditions
- Interventions
- Behavioral: Erickson hypnosis
- Sponsor
- University Hospital, Lille
- Collaborators
- France Parkinson Association
- Start date
- 2020-08-08
- Primary completion
- 2024-08-16
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 4
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Men or women * 18 to 80 years old * idiopathic Parkinson's disease * without neurological co-morbidity * Suffering from chronic pain (for at least 3 months), related to Parkinson's disease * Having a pain intensity of at least 30 mm on the VAS (average intensity over the previous week) for Parkinson's disease-related pain * antiparkinsonian, analgesic and psychotropic treatments stable for 1-month * having a health insurance * signed informed consent form Exclusion Criteria: * Patient with a neurological condition other than Parkinson's disease or with an atypical Parkinson's syndrome * Early untreated patient * Patient with acute intercurrent pain * Patient whose pain is mainly attributable to another pathology (rheumatoid arthritis, spondyloarthritis ankylosing, diabetic neuropathy, cancer, etc.) * Patient with cognitive impairment objectified by a score at the Montreal Cognitive Assessment (MoCA) \<24 * Patient with hallucinations and/or psychosis (MDS-UPDRS 1.2\> 1) * Patient with a apathy (MDS-UPDRS 1.5\> 1) * Patient with disabling dyskinesia (MDS-UPDRS) 4.1 AND 4.2\> 1) * Patient under the protection of adults * Pregnant or lactating woman
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04259203